METHODS: Patients throughout the US with self-described complications of vaginal mesh were recruited through advertisements to complete an internet-based anonymous survey. All patients filled out the PCS and the Genitourinary Pain Index (GUPI) questionnaire. The PCS is a 13-question survey with scores ranging from 0-52. Previous studies have established distribution of scores from subjects with chronic pain, with a score of 30 or higher representing the highest quartile, thus a score 30 was used to define high pain catastrophizing. Additional data was abstracted including age, number of previous pelvic surgeries, and intent to sue. Statistical analysis was performed using c 2 test and t-test for categorical and continuous variables, respectively.
INTRODUCTION AND OBJECTIVES: The ProtecT trial reported excellent outcomes for patients with localized prostate cancer (PCa) treated with radical prostatectomy (RP) . We aimed at assessing the generalizability of the ProtecT trial in men treated with RP at two high-volume institutions.
METHODS: 20,391 PCa patients aged 50-69 years treated with RP at two centers were included. We evaluated changes in disease characteristics over the study period and we identified patients who fulfilled the ProtecT criteria (cT1-cT2 and PSA <20ng/ml). Kaplan-Meier analyses assessed time to biochemical recurrence (BCR), clinical recurrence (CR), cancer-specific mortality (CSM), and overall mortality. A graphical illustration of the 10-year CSM and other-cause mortality (OCM) rates was generated using competing-risks Poisson regression analyses after stratifying patients according to eligibility in the ProtecT trial.
RESULTS: The proportion of biopsy Gleason 8-10, PSA >20 ng/ml, and high-risk disease increased over time (5.1 vs. 18.8% and 6.9 vs. 9. 1% and 13.3 vs. 24.6% for 1999-2005 vs. 2014-2016; all P<0.001) . Overall, 18,555 (91.0%) patients fulfilled the ProtecT criteria. The proportion of eligible individuals decreased over time (91.2 vs. 89.7% for 1999-2005 vs. 2014-2016, respectively; P¼0.02) . The median PSA and the proportion of biopsy Gleason 8-10 were higher among men treated at referral centers compared to what reported in ProtecT (6.5 vs. 4.9 ng/ml and 9.0 vs. 2%; P<0.001). When considering patients eligible for the ProtecT, the proportion of biopsy Gleason score 8-10 and median PSA increased over time (3.8 vs. 15.7% and 6.3 vs. 7.1ng/ml for 1996-2005 vs. 2014-2016; all P<0.001) . Median follow-up was 50 months. The 10year BCR-, CR-, and CSM-free survival rates were higher in men eligible for the ProtecT trial as compared to those not eligible (74.2 vs. 42.6% and 95.4 vs. 79.0% and 98.8 vs. 91.4%; all P<0.001) and comparable to what observed in the ProtecT. The risk of dying from OCM was substantially higher than the risk of dying from PCa among men eligible for the ProtecT (6.9 vs. 2%). Conversely, in non-eligible patients the 10-year CSM and OCM rates were 9.7 vs. 7.8%.
CONCLUSIONS: A migration towards higher Gleason scores and PSA levels at diagnosis occurred over recent years. More than 10% of men treated at referral centers should have been excluded from the ProtecT trial due to less favourable characteristics. These patients are more likely to die from PCa than from OCM thus being the optimal candidate for testing the role of primary treatment in randomized trials.
Source of Funding: none

PD51-02 IDENTIFYING THE OPTIMAL CANDIDATE FOR EARLY SALVAGE RADIATION THERAPY AFTER RADICAL PROSTATECTOMY FOR PROSTATE CANCER: A LONG-TERM MULTI-INSTITUTIONAL ANALYSIS
INTRODUCTION AND OBJECTIVES: The effectiveness of salvage radiation therapy (SRT) may be limited to specific categories of patients. We aimed at identifying the optimal candidate for SRT.
METHODS: The study included 693 node-negative patients who received SRT at six tertiary referral centres for either PSA rising after RP, or PSA persistence after surgery that was defined as PSA level 0.1 ng/ml at 1 month after RP. The study outcome consisted of distant metastasis after SRT: retroperitoneal (M1a), skeletal (M1b), and visceral metastasis (M1c). Regression tree analysis was used to develop a distant metastasis risk-stratification tool. Covariates consisted of pT stage (pT3a vs. pT3b), pathologic Gleason (7 vs. 8), surgical margins (negative vs. positive), post-operative undetectable PSA (no vs. yes), and PSA level at SRT. RESULTS: At a median follow-up of 96 months, 82 (12%) patients developed distant metastasis. The metastasis location was retroperitoneal, skeletal, and visceral in 18 (2.6%), 33 (4.8%), and 9 (1.3%) patients, respectively. Using regression tree analysis, 5 risk groups for distant metastasis were identified: 1) very low-risk: undetectable PSA after RP, Gleason sum 7, and pT3a; 2) low-risk: undetectable PSA after RP, Gleason sum 7, and pT3b; 3) intermediate-risk: undetectable PSA after RP, and Gleason sum 8; 4) high-risk: PSA persistence after RP, and Gleason sum 7); 5) very high-risk: PSA persistence after RP, and Gleason sum 8. Frequencies and proportions of the five groups were 294 (42%), 211 (30%), 110 (16%), 58 (8%), 20 (3%), respectively. Metastasis-free survival at 8 years of the five groups was 86%, 75%, 74%, 72%, and 60%, respectively (p¼0.003). The PSA level at SRT was significantly associated with the risk of distant metastasis in low-, intermediate-, and high- 
INTRODUCTION AND OBJECTIVES:
Estimating the risk of competing mortality is of importance in tailoring optimal individual management strategies in patients with early prostate cancer. Patients selected for radical prostatectomy at an age of 70 years or older, a stricter selection for good risks may influence the prognostic significance of individual risk factors for competing mortality. No generally accepted tool is available in order to predict competing mortality in in this particular population.
METHODS: Using proportional hazard models for the subdistribution of competing risks according to Fine and Gray, we studied 2961 consecutive patients treated at our institution between 1992 and 2007 in order to determine which parameters predict competing mortality in patients selected for radical prostatectomy at an age of 70 years or older and compared the prognostic impact of individual parameters with that in their younger counterparts. The mean follow-up was 11.2 years.
RESULTS: Three common diseases (diabetes mellitus, chronic lung disease and other cancer) which predicted competing mortality in younger men were no predictors of competing mortality in men selected for radical prostatectomy at an age of 70 years or older (hazard ratios, HRs, lower than 1). Beside age (HR per year 1.08, p¼0.0255), peripheral vascular disease (HR 2.33, p¼0.0195), cerebrovascular disease (HR 2.23, p¼0.0242), American Society of Anesthesiologists (ASA) physical status class 3 (HR 2.19, p<0.0001), current smoking (HR 2.18, p¼0.0098) and lower or unknown level of education (HR 2.07, p¼0.0002) were independent predictors of competing mortality in patients aged 70 years or older. With adding one risk point for each of these parameters, the resulting score compared favorably with five conventional comorbidity measures (Akaike information criterion 1425 versus a range between 1452 for the unweighed Charlson score and 1460 for the modified Lee mortality index). CONCLUSIONS: Conclusions: Combining these five conditions in a score might provide a superior comorbidity measure in patients undergoing radical prostatectomy at an age of 70 years or older. complications after radical prostatectomy (RP). The aim of our study was to assess the impact of depression and anxiety on functional outcome in patients undergoing RP for prostate cancer (PCa).
METHODS: A total of 3890 patients who underwent RP between 2004 and 2016 were analyzed. Patients with adjuvant radiation within three or twelve months after RP were excluded. For erectile function (EF) assessment, additional exclusion criteria consisted of androgen deprivation therapy (ADT) within three or twelve months after RP, preoperative erectile dysfunction and none or only unilateral nerve sparing. Baseline depression and anxiety were assessed using the Patient Health Questionnaire-(PHQ-) 4 and categorized into 0-2 (normal), 3-5 (mild) and 6 (moderate to severe) points. Urinary continence (UC) was defined as the use of zero or 1-safety pad per 24 hours. Recovery of EF was defined as a score of 3 points in the second question of the IIEF-5 questionnaire: 00 (...)how often were your erections stiff enough for penetration? 00 . Multivariable logistic regression analyses adjusted for age, BMI, pathological tumor stage and nervesparing technique (bi-vs. unilateral vs. none; only in UC analysis) were used to assess the impact of depression and anxiety on UC and EF.
RESULTS: Overall 1-week UC rates were 20.6%, 18.5% and 13.1% for PHQ-4 scores 0-2, 3-5 and 6. For the same groups, the rates were 75.1%, 73.7% and 69.4% for 3-months and 84.2%, 86% and 75% for 1-year UC. Multivariable regression analyses confirmed the adverse impact of a higher PHQ-4 score on 1-week and 1-year UC. Odds ratio for 1-week, 3-months and 1-year UIC were 1.86, 1.42 and 1.99 for patients with PHQ-4 scores 6 (p¼ 0.003, 0.1 and 0.02). EF rates at 3-months were 47.9 %, 43.1% and 47.4% for PHQ-4 scores 0-2, 3-5 and 6. For the same groups, 1-year EF recovery rates were 63.7%, 57.9% and 58.6%. No statistically significant difference was found either in uni-or in multivariable analyses. However, we observed a significantly higher use of PDE-5-inhibitors (PDE-5-I) and intracavernous injection therapies (ICI) among men with PHQ-4 score of 6.
CONCLUSIONS: A higher PHQ-4 score, representative for depression and anxiety, is significantly associated with worse 1-week and 1-year UC. We did not found a correlation between depression and anxiety and EF recovery, however men with higher PHQ-4 scores were more likely to use erectile dysfunction treatment. Therefore, further studies and higher patient samples are necessary. 
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INTRODUCTION AND OBJECTIVES:
The optimal primary treatment for men with clinically high-risk prostate cancer (PCa) is controversial as both radical prostatectomy (RP) and radiotherapy (RT) are associated with potential advantages and disadvantages. Our objective was to compare the overall mortality-free survival of high-risk PCa patients treated with primary RP vs. primary RT with neoadjuvant/ adjuvant androgen deprivation therapy [ADT], within the National Cancer Data Base (NCDB).
METHODS: Within the NCDB, a total of 87,875 high-risk PCa patients fulfilled our pre-specified inclusion criteria (53, 197 in RP group and 34, 678 in RT+ADT group) . We employed an instrumental variable analysis (IVA) approach using the yearly rate of RP as the instrument, to mitigate the impact of both observed and unobserved confounders. Multiple sensitivity analyses were performed, including stratification for age, comorbidity, ADT utilization and high dose (>75.6 Gy) RT. In addition, the overall mortality-free survival of RP was compared to that of RT reported in three recently published randomized controlled trails (RCTs), after selecting only RP patients who fitted inclusion/exclusion criteria of these RCTs.
